Welcome to our dedicated page for Regentis Biomaterials SEC filings (Ticker: RGNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regentis Biomaterials Ltd. (RGNT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 6-K and registration materials related to its NYSE American listing. As a foreign private issuer, Regentis uses Form 6-K to furnish press releases and other information that it makes public in its home market or files with other regulators.
Recent 6-K filings incorporate press releases on clinical and scientific developments for GelrinC, the company’s lead cell-free, off-the-shelf hydrogel implant for focal articular knee cartilage injuries. For example, a 6-K furnishes the press release titled “Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation,” summarizing Phase II data published in the journal Cartilage and describing MRI-based MOCART scores at 24 months. Another 6-K includes the press release “Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC,” outlining patent protection for the liquid, ready-to-use formulation and solvent-free production processes.
Filings also cover corporate and governance events, such as changes in executive leadership, and provide formal notice of these developments under the Exchange Act. In addition, the company’s registration statement on Form F-1 and related documents detail its initial public offering of ordinary shares and listing on the NYSE American under the symbol RGNT.
On Stock Titan, these SEC documents are updated as they are made available through EDGAR. AI-powered tools can help readers quickly understand the key points in each filing, such as clinical endpoints, regulatory milestones, intellectual property disclosures, and changes in management, without needing to parse every page manually.
REGENTIS BIOMATERIALS LTD. Chief Medical Officer Galit Reske reported initial holdings of an employee stock option to buy 67,961 shares of common stock. The option has a $4.00 exercise price and expires on February 23, 2037.
The option was granted on February 23, 2026 and vests over three years. One-sixth of the option vests six months after the grant date, and one-twelfth vests on the last day of each subsequent three-month period, subject to continued employment.
REGENTIS BIOMATERIALS LTD. director and Chief Executive Officer Ehud Geller filed an initial Form 3 detailing his derivative holdings in the company. He reports fully vested employee stock options to acquire 182,000 shares of common stock at an exercise price of $0.01 per share, expiring on December 5, 2035, and additional fully vested options over 283,533 shares at the same exercise price, expiring on March 20, 2035. He also reports directly held warrants that are currently exercisable to purchase 92,821 ordinary shares at an exercise price of $5.00 per share, with a three-year term ending on December 5, 2028. The filing records these derivative positions but does not report any new purchases or sales.
REGENTIS BIOMATERIALS LTD. filed an initial insider ownership report for board member Susan Alpert, PHD MD. The Form 3 identifies her as a director of the company but does not list any equity transactions or changes in holdings at this time.
REGENTIS BIOMATERIALS LTD. director Valentine Keith has filed an initial ownership report showing an employee stock option to buy common stock. The option covers 37,500 underlying shares of common stock at an exercise price of $1.46 per share and expires on January 9, 2029. A footnote states that this option grant is fully vested as of the reported date, meaning all 37,500 underlying shares are currently exercisable under the option, although no exercise is reported here.
REGENTIS BIOMATERIALS LTD. Chief Accounting Officer Arie Gordashnikov filed an initial insider ownership report on Form 3. This filing establishes his status as an executive officer of the company and provides the baseline disclosure of his position for future insider trading reports. No transactions are reported.
REGENTIS BIOMATERIALS LTD. director Efraim Cohen-Arazi has filed an initial Form 3, which is a required statement of beneficial ownership when someone becomes an insider. The filing establishes his reporting status as a director of the company but does not show any transactions.
REGENTIS BIOMATERIALS LTD. director Ben-Elazar Pini reported his initial ownership position in a Form 3 filing. He holds employee stock options covering 39,295 shares of common stock at an exercise price of $0.01 per share, fully vested and expiring on January 23, 2035.
He also holds warrants to purchase 15,831 ordinary shares of common stock at an exercise price of $5.00 per share, which are currently exercisable and have a three-year term, expiring on December 5, 2028. In addition, he directly owns 128,666 ordinary shares with no par value per share. The filing reflects holdings only and does not report new purchases or sales.
REGENTIS BIOMATERIALS LTD. Chief Financial Officer Gon Ori reported an initial holding of employee stock options. These options allow the purchase of 84,951 shares of common stock at an exercise price of $4.0000 per share and expire on February 23, 2037.
The option was granted on February 23, 2026 and vests over three years, with one-sixth vesting six months after the grant date and the remainder vesting quarterly, subject to continuous employment through each vesting date.
REGENTIS BIOMATERIALS LTD. director Jeff Dykan filed an initial ownership report showing indirect positions held through venture funds he manages. The filing lists 270,473 ordinary shares held by SCP Vitalife Partners II L.P. and 130,465 ordinary shares held by SCP Vitalife Partners (Israel) II L.P. Dykan is the general partner of these SCVP entities and holds voting and dispositive power over their shares. In addition, the SCVP funds hold warrants that are currently exercisable for 6,122 and 2,083 ordinary shares at an exercise price of $5.00 per share, each with a three-year term expiring on December 5, 2028.
Regentis Biomaterials Ltd. files an amended Form 20-F for the year ended December 31, 2025 to correct formatting errors in two financial statement pages caused by its financial printer. The amendment does not update or change any other disclosures or reflect subsequent events.
The company reports 5,179,378 ordinary shares outstanding as of December 31, 2025 and describes itself as a regenerative medicine business focused on orthopedic cartilage repair using its Gelrin hydrogel platform. Its lead product candidate GelrinC holds a CE mark in Europe, and the filing highlights ongoing funding needs and going concern risks.